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Harmonization of commercial assays for PINP; the way forward
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Abstract
Introduction—In order to examine the agreement between current commercial assays, a multi-
center study was performed for PINP in serum and plasma.
Methods—The automated methods for PINP (Roche Cobas and IDS iSYS) gave similar results. 
A significant proportional bias was observed between the two automated assays and the Orion 
radioimmunoassay (RIA) for PINP.
Results—Results from other published studies comparing PINP values among these three assays 
broadly support our findings. Taken together, these results confirm that harmonized PINP 
measurements exist between the two automated assays (Roche Cobas and IDS iSYS) when the 
eGFR is > 30 mL/min/1.73m2, but a significant bias exists between the Orion RIA and the two 
automated assays.
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Conclusion—Therefore, in subjects with normal renal function, PINP results reported by the 
Roche Cobas and IDS iSYS assays are similar and may be used interchangeably, and similar 
reference intervals and treatment targets could be applied for the two automated assays. 
Harmonization between the automated assays and the RIA is potentially possible with the use of 
common calibrators and the development of a reference method for PINP. This should also help 
ensure that any new commercial assay developed in the future will attain similar results. IOF and 
IFCC are committed to working together towards this goal with the cooperation of the reagent 
manufacturing industry.
Summary
International Federation of Clinical Chemistry and Laboratory Medicine and The International 
Osteoporosis Foundation Joint Committee on Bone Metabolism believes that the harmonization of 
PINP assays is an achievable and practical goal.
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Osteoporosis is a disease characterized by low bone mass and micro-architectural 
deterioration of bone tissue, leading to an increased risk of fracture with associated 
morbidity and mortality [1]. Its prevalence is increasing in part due to an aging population, 
resulting in a major public health burden globally [2]. When subjects with a high fracture 
risk are identified and the appropriate treatment is instituted and adhered to, the fracture risk 
can be significantly reduced [3]. Biochemical markers of bone turnover may be useful in 
monitoring the response to treatment and as a potential adjunct to improving adherence to 
treatment, which has to be long-term [4]. The International Osteoporosis Foundation (IOF) 
and the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) 
Joint Working Group on Bone Marker Standards (WG-BMS) recommended one bone 
formation marker, namely the procollagen type I N-propeptide (PINP), and one bone 
resorption marker, the C-terminal telopeptide of type I collagen (CTX), be used as reference 
markers for clinical research studies [5]. They further recommended that standardization or 
harmonization of commercial assays be achieved in order to establish internationally agreed 
decision limits and target values for these markers in the management of osteoporosis. This 
perspective addresses issues related to the harmonization of commercial PINP assays.
PINP was first isolated from amniotic fluid as “fetal antigen 2”, and amino acid sequencing 
identified the high-molecular weight peptide (intact form, MW 35,000) as a heterotrimer of 
two 14,250 MW proα1-chains and a 5500 MW proα2-chain [6]. However, its molecular 
structure has not been accurately characterized. Currently, there are three commercially-
available immunoassays for the measurement of PINP in blood, two of which are available 
on automated platforms: Immunodiagnostic Systems plc on the iSYS automated analyzer 
(IDS, Boldon, UK) and Roche Diagnostics (Mannheim, Germany) instruments. Both use an 
electrochemiluminescence immunoassay (ECLIA) technology. The third manual 
radioimmunoassay (RIA) is produced by Orion Diagnostica (UniQ PINP RIA, Orion 
Diagnostica, Espoo, Finland). For obvious reasons, automated assays are less labor 
intensive, with a higher throughput and quicker turnaround times. Unlike RIAs, automated 
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assays are not hampered by drawbacks associated with the use of radioactive reagents such 
as the necessity for dedicated facilities and specially trained staff, which have led to major 
reductions in the use of RIA assays and the facilities for performing such assays globally. 
However, only the Orion Diagnostica PINP assay is currently approved by the FDA and 
therefore the only method available in the USA for clinical use. The automated assays are 
widely used in clinical laboratories elsewhere worldwide.
The PINP calibrator used in the Orion RIA is purified from human ascitic fluid and 
characterized by electrophoresis. The value assignment of the first purified antigen stock 
standard was performed by amino acid quantitative analysis (Orion PINP RIA kit insert). 
The IDS assay calibrator, similar to the Orion assay calibrator, is a purified trimeric PINP, 
and the assay is standardized against the manufacturer’s master curve [7]. The Roche 
Diagnostics assays uses a synthetic amino procollagen peptide made from pre-procollagen 
α11 as the standard. The assay is calibrated against the precisely-defined standard by 
weighing native P1NP into an analyte-free human serum matrix [7]). The IDS iSYS assay 
and the Orion Diagnostica assay are specific to the trimeric (intact PINP) molecule and do 
not cross react with the monomer or fragments of the PINP molecule, which accumulate in 
circulation in patients with chronic kidney disease stages 4 and 5 (i.e., when the glomerular 
filtration rate decreases to approximately less than 30 ml/min/1.73 m2). The Roche PINP 
assay, on the other hand, cross reacts with the monomeric fragments in addition to 
recognizing the intact molecule (total PINP) [7].
A lack of knowledge of the molecular structure of PINP and the different peptides measured 
by the intact and total PINP assays pose problems in the standardization of these assays. 
Therefore, the IFCC/IOF Joint Committee on Bone Metabolism believes that the 
harmonization of PINP assays is the more practical goal. In order to examine the agreement 
between current commercial assays, a multi-center study was performed for PINP in serum 
and plasma among four laboratories in Europe [8]. PINP was measured in serum and EDTA 
plasma samples from 796 patients with normal renal function (eGFR > 30 mL/min/1.73m2) 
present in osteoporosis clinics. All assays gave equivalent results for both serum and EDTA 
plasma, indicating that both matrices are acceptable and may be used interchangeably [8].
The automated methods for PINP (Roche Cobas and IDS iSYS) gave similar results (Fig. 
1a) [8]. On the other hand, a significant proportional bias was observed between the Orion 
RIA and the two automated assays (i.e., a correlation was observed, but agreement was not 
shown between the automated methods and the RIA Fig.1b) [8]. Results from other 
published studies comparing PINP values among these three assays broadly support our 
findings [9, 10]. Taken together, these results confirm that harmonized PINP measurements 
exist between the two automated assays (Roche Cobas and IDS iSYS) when the eGFR is > 
30 mL/min/1.73m2, but a significant bias exists between the Orion RIA and the two 
automated assays. The good news is that in subjects with normal renal function, PINP results 
reported by the Roche Cobas and IDS iSYS assays are similar and may be used 
interchangeably. The perception that the two automated assays are used by the vast majority 
of laboratories worldwide outside of the USA (based on data from external quality assurance 
providers) leads us to conclude that similar reference intervals and treatment targets could be 
applied in those instances. This agreement does not extend to the Orion RIA, but the use of a 
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single assay for PINP within the USA should ensure harmonized results in routine service 
for clinical practice within that country. However, if the universal harmonization of PINP 
assays is to be achieved, and this is crucial for international multicentre trials as well as for 
the development of clinical guidelines with universally applicable reference intervals and 
treatment targets, then further work will be required in order to harmonize all three assays 
for PINP. Since there is an excellent correlation between the RIA and the automated assays, 
harmonization between the automated assays and the RIA is potentially possible with the 
use of common calibrators and the development of a reference method for PINP. This should 
also help ensure that any new commercial assay developed in the future will attain similar 
results and would be a step forward in the use of P1NP as a biomarker in the management of 
osteoporosis. The International Federation of Clinical Chemistry and Laboratory Medicine 
and The International Osteoporosis Foundation are committed to working together towards 
this goal with the cooperation of the reagent manufacturing industry.
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Fig. 1. 
a Passing-Bablock regression plot of PINP values observed on IDS iSYS vs. Roche Cobas 
which show good agreement (Cobas = 0.91x iSYS+2.6). (BE Belgium, DK Denmark, GR 
Greece, UK United Kingdom). b Passing-Bablock regression plot of PINP values observed 
on IDS iSYS vs. Orion RIAwhich show a significant proportional difference iSYS = 
1.35xOrion RIA−3.2). (BE Belgium, DK Denmark).
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